AI innovation for personalized immunotherapy for Cancer Patients

About NormaxAI

NormaxAI Inc. is a C-corporation in Delaware USA specializing in AI innovation for personalized medicine with integrated hardware and software solutions.

At NormaxAI, we are committed to helping cancer patients with personalized immunotherapy [n=1] by leveraging the power of safe artificial intelligence (AI).

NormaxAI Offering

Educated Antigen Receptor Therapy (EARTh) GMP Process is under deployment at MTIF GMP Clean Room in cooperation with BiocommAI and Google Cloud/Google Deepmind and Thermo Fisher Nucleic Acid Therapeutics Group.

The first Virtual Tumor Board by NormaxAI is under deployment at MTIF-NTU in cooperation with BiocommAI.

We envision a future where cancer patients have access to personalized, effective, and affordable treatments. By harnessing the power of AI and cutting-edge biotechnology, we aim to improve patient outcomes, extend lives, and ultimately, contribute to a world free from cancer.

Peter A. Jensen, CEO, NormaxAI

Contact

  • normax.ai

  • info@nrvx.net